Stephanie Sutton

Novartis is looking to advance its personalized medicine treatment programs by entering into a definitive agreement to acquire Genoptix, a laboratory offering personalized diagnostic services, for approximately $470 million or $25 per share.

The European Medicines Agency (EMA) has initiated a safety review of Sanofi's anti-arrhythmic medicine Multaq following reports of serious liver injury in patients.

Johnson & Johnson's run of quality issues, recalls and other bad news continues with yet another product recall.

GlaxoSmithKline is expecting to pay $3.4 billion to settle legal charges relating to its diabetes drug Avandia, as well as sales and promotional practices in the US for other products.

The EU Commission is on the lookout for "potentially problematic patent settlements" and has asked several pharma companies to submit copies of their patent settlement agreements made between originator and generic companies.

The EU Commission is on the lookout for "potentially problematic patent settlements" and has asked several pharma companies to submit copies of their patent settlement agreements made between originator and generic companies.

GlaxoSmithKline is expecting to pay $3.4 billion to settle legal charges relating to its diabetes drug Avandia, as well as sales and promotional practices in the US for other products.

With counterfeit medicines increasingly appearing in legitimate supply chains and even in the clinical stages of product development, a recent white paper has outlined practical steps that may help companies address the issue of counterfeits and diverted products.

Urgent changes are required in the UK's regulation and governance of health research because medical advances are currently being stifled by unnecessary delays, bureaucracy and complexity.

With dozens of prescription drugs soon to lose patent protection and few likely blockbusters in industry pipelines, drug developers are "aggressively" changing the way they do R&D, according to the Tufts Center for the Study of Drug Development (CSDD).

With dozens of prescription drugs soon to lose patent protection and few likely blockbusters in industry pipelines, drug developers are "aggressively" changing the way they do R&D, according to the Tufts Center for the Study of Drug Development (CSDD).

The threat of counterfeit medicines in the next year will be more severe than ever, according to a survey of 1000 companies conducted in October 2010 by Pharma IQ.

GlaxoSmithKline has responded to a recently aired 60 Minutes program about the whistleblower lawsuit that resulted in GSK paying $750 million to settle civil and criminal charges.

Looking to 2011, the European Medicines Agency (EMA) has adopted its work program and budget for the year, as well as a new Road Map to 2015.

Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin from the worldwide market and discontinued all ongoing trials.

Figures released by the EMA regarding the evaluation of marketing authorization (MA) applications show a significant decline in the number of approved products for 2010 — only 38 positive opinions have been issued as of October 2010 compared with 117 in 2009.

Figures released by the European Medicines Agency regarding the evaluation of marketing authorization (MA) applications show a significant decline in the number of approved products for 2010.

Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin from the worldwide market and discontinued all ongoing trials.

China and India will become the world leaders in innovation during the next decade, according to an international survey released by AstraZeneca.

Sanofi Pasteur has formally withdrawn its application to the European Medicines Agency (EMA) for a centralized marketing authorization for its pandemic influenza vaccine Emerflu.

Sanofi Pasteur has formally withdrawn its application to the European Medicines Agency (EMA) for a centralized marketing authorization for its pandemic influenza vaccine Emerflu.

China and India will become the world leaders in innovation during the next decade, according to an international survey released by AstraZeneca.

Roche has announced implementation plans for its Operational Excellence Program, announced in September, which include eliminating 4800 positions worldwide over the next 2 years — 6% of its current workforce.

Following new clinical data and a request from the FDA, Xanodyne Pharmaceuticals has agreed to withdraw its prescription pain products Darvon and Darvocet (propoxyphene) from the US market.

European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission (EC), with particular support being seen in the area of regenerative medicines, including stem cell research and embryonic stem cell research.

Building on their long-standing relationship, GlaxoSmithKline and Brazil's Oswald Cruz Foundation (Fiocruz) have announced a new collaboration to research and develop innovative medicines for neglected tropical diseases.

European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission.

Sanofi-aventis has told Genzyme to stand aside and let the shareholders decide on whether an acquisition should take place.

The market for orally disintegrating and fast dissolving tablets could exceed revenues of $13 billion by 2015 based on upward global growth trends, according to a report from Technology Catalysts.

The market for orally disintegrating and fast dissolving tablets could exceed revenues of $13 billion by 2015 based on upward global growth trends, according to a report from Technology Catalysts International, a technology transfer and business consulting firm based in Virginia.